Skip to main content

Table 2 Correlations of pathway modules with outcome in breast cancer

From: Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules

  ER+ (n = 785)    ER- (n = 438)   
  HR 95%CI Pval HR 95%CI Pval
MYC 1.5 1.16-1.95 0.002 0.82 0.58-1.16 0.27
E2F3 2.23 1.7-2.92 < 10-8 0.71 0.5-1 0.05
RAS 1.38 1.06-1.79 0.02 1.13 0.8-1.59 0.5
ERBB2 1.06 0.82-1.38 0.64 1.29 0.91-1.82 0.15
EGFR 0.93 0.72-1.21 0.59 1.82 1.28-2.59 < 0.001
AKT 1.29 0.99-1.67 0.06 1.49 1.05-2.11 0.02
IL12 0.88 0.68-1.15 0.35 0.52 0.36-0.74 < 0.001
IL4 0.96 0.74-1.25 0.77 0.93 0.66-1.31 0.69
IL2 0.88 0.68-1.14 0.32 0.7 0.5-1 0.05
IL13 1.28 0.98-1.66 0.07 1.29 0.91-1.82 0.15
IFNG 1.09 0.84-1.42 0.5 0.58 0.41-0.82 0.002
TGFB 0.93 0.71-1.2 0.57 1.65 1.16-2.34 0.004
  1. For ER+ and ER- breast cancers in Set1 and for each pathway, we give the hazard ratio, 95%CI and the log-rank test P-value from a stratified Cox-proportional hazards regression model with cohorts as strata and with distant metastasis free survival (DMFS) as clinical endpoint. Pathway activation levels were divided into high/low activity levels according to values larger/lower than the median. Number of samples is given by n.